Financial Performance - For 2025, AGNC generated total comprehensive income of $1.74 per diluted common share and an economic return of 22.7% on tangible common equity, compared to $0.84 and 13.2% in 2024 [172]. - Net income available to common stockholders reached $1,509 million in 2025, compared to $731 million in 2024, reflecting a significant increase of 105.0% [212]. - Comprehensive income available to common stockholders was $1,777 million in 2025, compared to $657 million in 2024, an increase of 170.5% [212]. - Economic interest income for fiscal year 2025 reached $4,097 million, a 28% increase from $3,198 million in 2024 [221]. - The total gain on investment securities for fiscal year 2025 was $2,472 million, a significant recovery from a loss of $1,147 million in fiscal year 2024 [245]. Investment Portfolio - The investment portfolio totaled $94.8 billion as of December 31, 2025, an increase of $21.5 billion for the year, with 30-year fixed-rate Agency RMBS and TBAs representing 95% of the portfolio [175]. - As of December 31, 2025, the investment portfolio totaled $94.8 billion, up from $73.3 billion in 2024, representing a growth of approximately 29% [190]. - The fair value of Agency RMBS increased to $81.1 billion in 2025 from $65.5 billion in 2024, reflecting a growth of about 24% [190]. - The total fixed rate Agency RMBS and TBA securities had a fair value of $90.5 billion in 2025, up from $74.0 billion in 2024, representing a growth of approximately 22% [190]. - The total investment securities, including TBA securities, had a fair value of $94.7 billion in 2025, up from $73.2 billion in 2024, marking an increase of approximately 29% [190]. Income and Expenses - Net spread and dollar roll income per diluted common share decreased to $1.50 in 2025 from $1.88 in 2024, primarily due to lower swap income [173]. - Economic interest expense for fiscal year 2025 was $2,276 million, significantly lower than $1,395 million in 2024, resulting in a cost of funds of 2.98% [232]. - The average net interest spread decreased to 1.92% in fiscal year 2025 from 2.42% in fiscal year 2024, reflecting an increase in average asset yield and aggregate cost of funds [241]. - Net interest income turned positive at $675 million in 2025, a substantial recovery from a net interest expense of $246 million in 2023 [212]. Market Conditions - The Federal Reserve's monetary policy shift toward lower short-term interest rates contributed to the positive performance of domestic fixed income asset classes [168]. - Looking ahead, net spread and dollar roll income are expected to benefit from lower funding costs and potential future rate cuts, despite higher hedging costs [180]. - The net supply of new Agency RMBS in 2026 is expected to be approximately $200 billion, with demand remaining robust from GSEs, banks, and other investors [170]. Securities and Rates - The weighted average coupon of the portfolio, excluding TBAs, increased to 5.19% as of December 31, 2025, compared to 5.03% in 2024 [176]. - The 30-Year Agency Current Coupon Yield decreased to 5.04% in 2025 from 5.83% in 2024, a decline of 79 basis points [186]. - The 30-Year Mortgage Rate also decreased to 6.16% in 2025 from 6.86% in 2024, a reduction of 70 basis points [186]. - The weighted average yield on investment securities (excluding TBA and forward settling securities) was 4.93% in 2025, compared to 4.77% in 2024, indicating an increase of 16 basis points [193]. Liquidity and Capital Management - AGNC's liquidity position at year-end was $7.6 billion in unencumbered cash and Agency RMBS, representing 64% of tangible equity [177]. - The company plans to maintain adequate liquidity and capital resources to fund operations and satisfy dividend distribution requirements, with primary sources including unencumbered cash and securities [248]. - Unencumbered assets totaled approximately $7.7 billion, or 65% of tangible equity, compared to $6.2 billion, or 67% of tangible equity, as of December 31, 2024 [262]. Employee and Corporate Governance - As of December 31, 2025, the workforce consisted of 54 full-time employees, with zero employee turnover over the past three years [40]. - 39% of employees were women and 31% were ethnically diverse as of December 31, 2025 [44]. - The company offers a 401(k) Savings Plan with Company matching contributions of 100% up to 6% of each employee's eligible compensation [46]. - The company was recertified as a Great Place to Work™ in 2023 based on employee feedback [41].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 OR (I.R.S. Employer Identification No.) 7373 Wisconsin Avenue, 22nd Floor Bethesda, Maryland 20814 (Address of principal executive offices) (301) 968-9315 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4717861 (State or other ju ...

Financial Performance - Fourth quarter 2025 net income was $43.2 million, or $1.03 per diluted share, compared to $14.4 million, or $0.35 per diluted share in the same period of 2024[1]. - Adjusted operating income for Q4 2025 was $48.9 million, or $1.17 per diluted share, up from $33.2 million, or $0.80 per diluted share in Q4 2024[2]. - Net income for the twelve months ended December 31, 2025, was $170,028,000, a 43.1% increase compared to $118,828,000 in 2024[20]. - Basic earnings per share rose to $4.21 in 2025 from $2.97 in 2024, reflecting a 41.8% increase[21]. - Total revenues for the twelve months ended December 31, 2025, reached $1,416,541,000, a 23.2% increase from $1,150,200,000 in 2024[20]. - Adjusted operating income for Q4 2025 was $61,758,000, compared to $48,855,000 in Q4 2024, marking a 26.4% increase[24]. - Annualized ROE improved to 17.5% in Q4 2025 from 7.2% in Q4 2024[21]. Premiums and Underwriting - Gross written premiums for Q4 2025 reached $439.5 million, a 13.2% increase from $388.4 million in Q4 2024[3]. - Net written premiums for the year ended 2025 were $1.4 billion, a 25.2% increase from $1.1 billion in 2024[4]. - Net earned premiums for Q4 2025 were $356,800,000, up 21.6% from $293,240,000 in Q4 2024[20]. - Total gross written premiums for the twelve months ended December 31, 2025, reached $2,166,317,000, a 24.3% increase from $1,743,249,000 in 2024[29]. - Accident & Health gross written premiums increased by 50.9% in Q4 2025, totaling $67,297,000 compared to $44,594,000 in Q4 2024[29]. - The Agriculture and Credit (Re)insurance segment saw a dramatic increase of 193.2% in gross written premiums for the twelve months ended December 31, 2025, totaling $346,212,000 compared to $118,070,000 in 2024[29]. - Specialty Programs gross written premiums increased by 75.1% in Q4 2025, reaching $91,304,000 compared to $52,151,000 in Q4 2024[29]. - The Surety segment reported a 21.1% increase in gross written premiums for Q4 2025, totaling $45,876,000 compared to $37,889,000 in Q4 2024[29]. - Underwriting income for Q4 2025 was $41,008,000, significantly higher than $12,239,000 in Q4 2024[25]. Assets and Equity - Total assets increased to $4,791,852,000 in 2025 from $3,729,478,000 in 2024, representing a growth of 28.5%[19]. - Stockholders' equity rose to $1,009.6 million at December 31, 2025, a 5.0% increase from $961.4 million at September 30, 2025[9]. - Tangible stockholders' equity as of December 31, 2025, was $921,525,000, up from $706,651,000 in 2024[28]. - Book value per share increased by 26% to $24.92 as of December 31, 2025, from $19.77 at the end of 2024[3]. - Book value per share increased to $24.92 in 2025 from $19.79 in 2024, a growth of 25.0%[21]. Liabilities and Reserves - Total liabilities increased to $3,782,287,000 in 2025 from $2,935,479,000 in 2024, an increase of 28.9%[19]. - Reserves for losses and loss adjustment expenses increased to $2,318,894,000 in 2025 from $1,782,383,000 in 2024, a rise of 30.0%[19]. Investment Income - Net investment income for Q4 2025 was $23.5 million, an increase of $2.8 million compared to Q4 2024[7]. - Net investment income for the twelve months ended December 31, 2025, was $83,619,000, compared to $80,600,000 in 2024[25]. - Interest expense for the twelve months ended December 31, 2025, decreased to $7,919,000 from $9,496,000 in 2024[25]. Strategic Goals - The company aims to continue building and maintaining winning positions across the specialty insurance market, leveraging its diversified portfolio[2].

Exhibit 99.1 FOR IMMEDIATE RELEASE: CONTACT: Geoff High, Vice President of Investor Relations 303-604-3924 DMC GLOBAL REPORTS FOURTH QUARTER FINANCIAL RESULTS BROOMFIELD, Colo. - February 23, 2026 - DMC Global Inc. (Nasdaq: BOOM) today reported financial results for its fourth quarter ended December 31, 2025. During the fourth quarter, DMC made significant progress strengthening its balance sheet, management's primary objective for 2025. Net debt* was reduced by $11.4 million sequentially to $18.7 million, ...

On February 11, 2026, Great Lakes announced that it had entered into a definitive agreement for Saltchuk Resources, Inc. ("Saltchuk") to acquire the Company. The closing of the transaction will be subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino Act waiting period and the tender of shares representing at least one share more than a majority of Great Lakes' outstanding shares of common stock, and is expected to close in Q2 2026. Offshore Energy EXHIBIT 99.1 Great Lak ...

Financial Performance - ORIC Pharmaceuticals reported a net loss of $30.5 million for Q4 2025, compared to a net loss of $36.3 million in Q4 2024, reflecting a decrease of 16% year-over-year[15]. - Research and development (R&D) expenses for Q4 2025 were $25.9 million, down from $32.0 million in Q4 2024, a decrease of 19.5%[7]. - General and administrative (G&A) expenses increased to $8.7 million in Q4 2025 from $7.6 million in Q4 2024, a rise of 14.5%[7]. - Cash, cash equivalents, and investments totaled $392.3 million as of December 31, 2025, with an expected runway into the second half of 2028[7]. - Total assets increased to $408.9 million as of December 31, 2025, compared to $274.1 million in 2024, reflecting a growth of 49%[13]. Clinical Development - Rinzimetostat demonstrated a 55% PSA50 response rate and a 20% PSA90 response rate in mCRPC patients, with 76% achieving over 50% ctDNA reduction[5]. - Enozertinib showed a 67% overall response rate (ORR) in EGFR exon 20 NSCLC patients and a 100% intracranial ORR in patients with measurable CNS disease[5]. - ORIC anticipates initiating its first global Phase 3 registrational trial for rinzimetostat in mCRPC in the first half of 2026[6]. - The company expects multiple clinical data readouts for rinzimetostat and enozertinib in 2026, ahead of potential registrational trials[1]. Funding and Financial Position - The company raised $264 million from healthcare specialist funds, enhancing its financial position for future clinical trials[1].

Exhibit 99.1 News Release Allison Transmission Announces Fourth Quarter and Full Year 2025 Results INDIANAPOLIS, February 23, 2026 – Allison Transmission Holdings Inc. (NYSE: ALSN) today reported full year 2025 net sales of $3 billion with Adjusted EBITDA margin of 37.5 percent and net cash provided by operating activities of $836 million. David S. Graziosi, Chair, President and Chief Executive Officer of Allison commented, "Although 2025 presented meaningful macroeconomic challenges, we remained discipline ...

Financial Performance - For the year ended December 31, 2025, total operating expenses increased to $1,094.4 million, up from $226.0 million in 2024, representing a change of $868.4 million [489]. - The net loss for the year ended December 31, 2025, was $1,079.6 million, compared to a net loss of $221.3 million in 2024, marking an increase of $858.3 million [489]. - The company incurred a net loss of $1,079.6 million for the year ended December 31, 2025, with cash flows used in operating activities amounting to $322.9 million [503]. Operating Expenses - Research and development expenses rose significantly to $537.7 million in 2025 from $150.8 million in 2024, an increase of $386.9 million [489]. - General and administrative expenses surged to $556.7 million in 2025, compared to $60.2 million in 2024, reflecting a $496.5 million increase [489]. - Stock-based compensation expenses increased dramatically to $218.6 million in 2025 from $16.0 million in 2024, a rise of $202.6 million [491]. - Research and development expenses increased by $371.9 million for the year ended December 31, 2025, compared to the prior year, driven by a $202.6 million increase in stock-based compensation and a $165.5 million increase in oncology-related expenses for ivonescimab [493]. - General and administrative expenses rose by $496.5 million for the year ended December 31, 2025, primarily due to a $478.8 million increase in stock-based compensation [496]. - The company expects to incur significant expenses and increasing operating losses for the foreseeable future, particularly related to the development of ivonescimab [502]. - The company anticipates ongoing increases in general and administrative expenses as it scales its infrastructure to support the development of ivonescimab [496]. Clinical Trials and Research - The company completed enrollment in its HARMONi clinical trial in October 2024 and announced topline results in May 2025, showing a median progression-free survival (PFS) of 6.8 months for ivonescimab plus chemotherapy compared to 4.4 months for chemotherapy alone [472]. - The hazard ratio for PFS in the primary analysis was 0.52 (95% CI: 0.41 – 0.66; p<0.00001), indicating a statistically significant improvement [472]. - An additional ad hoc overall survival (OS) analysis in September 2025 showed a hazard ratio of 0.78 (95% CI: 0.62 – 0.98; nominal p=0.0332) for Western patients, with median OS of 17.0 months for ivonescimab compared to 14.0 months for placebo [476]. - The company submitted a Biologics License Application (BLA) in Q4 2025 for ivonescimab plus chemotherapy, with the FDA accepting the filing in January 2026 [478]. Cash Flow and Financing - Cash and cash equivalents, along with short-term investments, totaled $713.4 million as of December 31, 2025, providing sufficient cash to fund operating needs for at least the next 12 months [504]. - Net cash provided by financing activities for the year ended December 31, 2025, was $617.5 million, primarily from a private placement of $500.0 million [518]. - The company raised gross proceeds of $150.7 million from its ATM Agreement since inception, contributing to its liquidity [501]. - Net cash provided by financing activities for the year ended December 31, 2024 was $381.2 million, primarily due to $434.9 million from private placements and $43.0 million from the current ATM Agreement [519]. Commitments and Obligations - As of December 31, 2025, total unconditional purchase obligations, excluding lease commitments, are estimated to be approximately $18.0 million [527]. - The company has estimated lease commitments totaling $27.3 million as of December 31, 2025, with $3.5 million due within one year [521]. - The company has no capital commitments as of December 31, 2025 [520]. Debt and Notes - The Duggan February Note was amended to extend the maturity date from September 6, 2024 to April 1, 2025, with interest accruing at a minimum of 12% [525]. - The company repaid the $20 million Zanganeh Note on February 15, 2023, and the $400 million Duggan Promissory Note was also repaid using proceeds from the 2023 Rights Offering [524]. - The company entered into a Note Purchase Agreement for $520 million in bridge financing through three unsecured promissory notes [530]. - The company accrued cash interest of $7.3 million on the Duggan September Note, which was fully repaid on October 1, 2024 [526]. Tax Positions - The Company recorded unrecognized tax positions of $3.9 million, $2.1 million, and $1.1 million for the years ending December 31, 2025, 2024, and 2023, respectively [542]. - The Company has a full valuation allowance against deferred tax assets exceeding deferred tax liabilities, indicating that future tax benefits are unlikely to be realized [541]. - The Company has $0.9 million of outstanding research and development tax credits as of December 31, 2025, which are expected to be collected based on historical collection rates [549]. Risk Management - The Company is exposed to foreign currency exchange rate risk, particularly with the pound sterling and euro, but currently does not consider the impact material [547]. - The Company maintains a portfolio of cash, cash equivalents, and short-term investments to minimize interest rate risk, with no material exposure to changes in fair value due to interest rate fluctuations [548]. - The Company considers all material counterparties to be creditworthy, indicating low credit risk across its operations [549]. Stock Options and Dividends - The Company uses a Monte Carlo simulation model to estimate the fair value of stock options, with key assumptions including risk-free interest rates and stock price volatility [538]. - Stock option awards generally vest over terms of 3 or 4 years, and the Company estimates expected forfeitures at the time of grant [539]. - The Company has not paid and does not intend to pay dividends, reflecting its focus on reinvestment rather than shareholder payouts [544].

Exhibit 99.1 MEDIAALPHA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Fourth Quarter Revenue of $291 million and Record Transaction Value of $613 million; Record Transaction Value of $552 million in Property & Casualty Insurance Vertical Record Full-Year 2025 Revenue of $1.1 billion and Transaction Value of $2.2 billion Record Full-Year 2025 Net Income of $26.8 million and Adjusted EBITDA of $113.7 million (1) Board of Directors Doubles Share Repurchase Authorization to $100 million Los Ange ...